Necrotizing Fasciitis Secondary To Bevacizumab Treatment For Metastatic Rectal Adenocarcinoma

dc.contributor.author	Şendur, Mehmet A. N.
dc.contributor.author	Aksoy, Sercan
dc.contributor.author	Özdemir, Nuriye Yıldırım
dc.contributor.author	Zengin, Nurullah
dc.date.accessioned	2019-12-10T11:15:19Z
dc.date.available	2019-12-10T11:15:19Z
dc.date.issued	2014
dc.identifier.issn	0253-7613
dc.identifier.uri	https://doi.org/10.4103/0253-7613.125195
dc.identifier.uri	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912798/
dc.identifier.uri	http://hdl.handle.net/11655/15207
dc.description.abstract	Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor and it is used in metastatic colorectal patients. We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer. In our review of the literature, necrotizing fasciitis was not reported before or during bevacizumab treatment.
dc.relation.isversionof	10.4103/0253-7613.125195
dc.rights	info:eu-repo/semantics/openAccess
dc.title	Necrotizing Fasciitis Secondary To Bevacizumab Treatment For Metastatic Rectal Adenocarcinoma
dc.type	info:eu-repo/semantics/article
dc.relation.journal	Indian Journal of Pharmacology
dc.contributor.department	İç Hastalıkları
dc.identifier.volume	46
dc.identifier.issue	1
dc.identifier.startpage	125
dc.identifier.endpage	126
dc.description.index	PubMed
dc.description.index	WoS